Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients

被引:7
作者
Bitar R. [1 ]
Flores O. [1 ]
Reverte M. [1 ]
López-Novoa J.M. [1 ]
Macías J.F. [1 ,2 ]
机构
[1] Instituto Reina Sof́ia de Investigacíon Nefroĺogica, Departamento de Fisioloǵia y Farmacoloǵia, Universidad de Salamanca, 37007 Salamanca, Paseo de San Vicente s/n
[2] Departamento de Medicina, Servicio de Nefroloǵia, Hospital Cĺinico Universitario, Universidad de Salamanca, 37007 Salamanca, Paseo de San Vicente s/n
关键词
Angiotensing-converting enzyme inhibitor; Elderly; Hypertension; Non-dihydropyridine calcium channel blocker; Serum creatinine; Verapamil;
D O I
10.1023/A:1007123725297
中图分类号
学科分类号
摘要
This study analysed the effect of low doses of verapamil added to chronic treatment with angiotensin-converting enzyme (ACE) inhibitors on blood pressure and serum creatinine levels in eight elderly hypertensive patients who had a steady increase of serum creatinine while on ACE inhibitors. The study was performed in eight elderly hypertensive subjects, five men and three women (mean age 70 ± 2 years; systolic blood pressure 173 ± 4 mm Hg; diastolic blood pressure 99 ± 1 mm Hg) and serum creatinine of 1.60 ± 0.27 mg/dl before treatment. During an average of 25 weeks, ACE inhibitors significantly reduced both systolic and diastolic blood pressures, but serum creatinine levels were increased over basal levels (0,68 ± 0,20 mg/dl, p < 0.05). During an average of 10 weeks, the addition of verapamil did not decrease blood pressure further, but serum creatinine levels were reduced to baseline. Our study suggests that the addition of verapamil to ACE inhibitors can reverse ACE-induced increase in creatinine levels in elderly hypertensive patients in whom this side effect is observed.
引用
收藏
页码:165 / 169
页数:4
相关论文
共 34 条
  • [1] Materson B.J., Reda D.J., Preston R.A., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., Hamburger R.J., Fye C., Lakshman R., Gottdiener J., Ramirez E.A., Henderson W.G., Response to a second single antihypertensive agent used as monotherapy for hypertension after failure of the initial drug, Arch Intern Med, 155, pp. 1757-1762, (1995)
  • [2] Materson B.J., Reda D.J., Cushman W.C., Massie B.M., Freis E.D., Kochar M.S., Hamburger R.J., Fye C., Lakshman R., Gottdiener J., Ramirez E.A., Henderson W.G., Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo, N Engl J Med, 328, pp. 914-921, (1993)
  • [3] Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP), JAMA, 265, pp. 3255-3264, (1991)
  • [4] Medical Research Council trial of treatment of hypertension in older adults: Principal results, BMJ, 304, pp. 405-412, (1992)
  • [5] Dahlof B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., Wester P.-O., Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension), Lancet, 338, pp. 1281-1285, (1991)
  • [6] Staessen J.A., Fagard R., Thijs L., Celis H., Arabidze G.G., Birkenhager W.H., Bulpitt C.J., De Leeuw P.W., Dollery C.T., Fletcher A.E., Forette F., Leonetti G., Nachev C., O'Brien E.T., Rosenfeld J., Rodicio J.L., Tuomilehto J., Zanchetti A., Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension, Lancet, 350, pp. 757-764, (1997)
  • [7] The 6th report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI), Arch Intern Med, 157, pp. 2413-2446, (1997)
  • [8] Kendall M.J., Hypertension in the elderly, Basic Res Cardiol, 93, SUPPL 2, pp. 43-46, (1998)
  • [9] Gonzalez-Albarran O., Garcia Robles R., Ruilope L.M., Therapeutic implications and new perspectives for essential hypertension and renal damage, Kidney Int, 54, SUPPL 68, (1998)
  • [10] Williams G.W., Converting-enzyme inhibitors in the treatment of hypertension, N Engl J Med, 319, pp. 1517-1525, (1988)